When Novo Nordisk entered into an agreement with US company Dicerna two years ago, it had seen the potential in manipulating RNA, like many other players in the industry.
Danish financial daily Børsen reports that the deal concerns a specific form of RNA technology, called RNA interference, or RNAi, which aims to reduce the production of damaging proteins. Karin Conde-Knape, Senior Vice President of Global Drug Discovery at Novo Nordisk, calls the approach "clearly exciting".
Get full access for you and your coworkers.
Start a free company trial todayAlready a member? Log in.
More from MedWatch
GN Hearing top exec stops after 17 years – replacement found within own ranks
The CEO of hearing company GN Hearing's US subsidiary Audigy is now retiring after 17 years in the hot seat. The company, which was acquired by GN Hearing in 2016, has found his replacement within own ranks.
Pharma industry is discretely working against a global tax agreement
The pharmaceutical industry is fighting against a threat to companies' bottom lines: a global agreement which will harmonize corporation tax.
Pfizer upgrades guidance for sales of covid-19 vaccine
The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.
Astrazeneca shot shows no increased clot risk after two doses
Blot clots are not more likely after second Astrazeneca jab, data published in The Lancet suggests.
Boston Scientific reports significant growth in endoscopy business – grows 54 percent
In Q2, medtech firm Boston Scientific sold significantly more endoscopy products, which is the core business area of Danish company Ambu. The US giant is upgrading its guidance for the whole year.
Research Laboratory Technician, Immunology/Translational Research - ALK 
KLIFO is looking for a Senior QA Specialist for our Glostrup office 
Sponsor Oversight Lead - Genmab 
Employee for regulatory department 
Senior Validation Analyst, Zealand Pharma 
Senior Biostatistician - Vaccibody 
Associate Director, PV QA - Y-mAbs Therapeutics 
We are expanding in CleanZone and we are looking for a technical product specialist and technical project manager 
Business developer within Medical Diagnostics 
Analytical Coordinator - Symphogen 
Senior Clinical Supply Manager - Lundbeck 
(Senior) Regulatory Science Specialist - IWA Consulting 
Manager/Associate Director Regulatory Affairs - Ascendis Pharma